LBT Innovations (LBT) Stock Price, News & Analysis

LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia, the United States, Sweden, the United Kingdom, and Germany. Its products portfolio comprises Automated Plate Assessment System (APAS) Independence, a platform technology that automates culture-plate screening and interpretation; APAS Analysis Modules, an intelligent image analysis software that enables the screening of microbiology culture plates; APAS antimicrobial resistance (AMR) Analysis Module that reads and interprets antimicrobial susceptibility tests (ASTs) for the detection of AMR; and APAS PharmaQC, which provides automated imaging, analysis, and interpretation of microbiology culture plates used in environmental monitoring. The company's products pipeline also includes Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; Biofilm, a device for detecting the biofilms in the presence of mammalian tissues; and WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds. LBT Innovations Limited was incorporated in 2004 and is headquartered in Adelaide, Australia.